Senolytics · DQ cocktail

The rationale behind the DQ cocktail is that senescent cells survive by activating anti-apoptotic networks (SCAPs, senescent-cell anti-apoptotic pathways). No single senolytic covers them all: dasatinib disables ephrin-dependent kinases and preferentially clears senescent adipocytes and endothelial cells; quercetin inhibits BCL-2/BCL-xL, PI3K and serpins, acting best on endothelial and bone-marrow cells. Together they broaden the range of cell types purged (Zhu 2015; Kirkland/Tchkonia).

Human clinical evidence: Idiopathic pulmonary fibrosis (Justice 2019, EBioMedicine): first-in-human, open-label, n=14. An intermittent regimen (D 100 mg + Q 1250 mg, 3 days/week × 3 weeks) was associated with improved physical function (gait speed, 6MWT, SPPB battery). Diabetic kidney disease (Hickson 2019, EBioMedicine, PMID 31542391): 3 days of DQ reduced p16INK4a+ and p21+ senescent cells in adipose tissue and skin and lowered circulating SASP markers (IL-6, MMP-9) — the first direct proof of senescent-cell clearance in people. Postmenopausal bone (Nature Medicine 2024, phase 2 RCT, n=60): the resorption marker CTx did not change at 20 weeks, but the formation marker P1NP rose transiently (+16% at 2 and 4 weeks) — a mixed result showing the field has not yet demonstrated robust clinical efficacy.

Honest caveat: dasatinib is an oncology drug with real adverse effects (cytopenias, pleural effusion, bleeding) requiring medical prescription and monitoring. Outside trials, the DQ cocktail is experimental; the evidence proves senescence reduction but not yet hard clinical benefit. Quercetin alone is a weak senolytic.